Document Classification

Section Type: RESULTS

Text: Aripiprazole 10 mg/day showed significantly greater improvements (mean change [2 x SD]) than placebo on the NPI-NH Psychosis Subscale (-6. 87 [8. 6] versus -5. 13 [10. 0] ; F = 6. 29, df = 1, 422, p = 0. 013 by analysis of covariance [ANCOVA]) ; CGI-S (-0. 72 [1. 8] versus -0. 46 [1. 6] ; F = 4. 68, df = 1, 419, p = 0. 031 [ANCOVA]) ; BPRS Total (-7. 12 [18. 4] versus -4. 17 [21. 6] ; F = 4. 72, df = 1, 399, p = 0. 030 [ANCOVA]) ; BPRS Core (-3. 07 [6. 9] versus -1. 74 [7. 8] ; F = 7. 30, df = 1, 407, p = 0. 007 [ANCOVA]) ; CMAI (-10. 96 [22. 6] versus -6. 64 [28. 6] ; F = 5. 23, df = 1, 410, p = 0. 023 [ANCOVA]), and NPI-NH Psychosis response rate (65 versus 50 % ; chi (2) = 5. 52, df = 1, p = 0. 019 [CMH]).